Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 10/2007

01.10.2007 | Original Paper

Large volume loading to prevent cisplatin-induced nephrotoxicity during negative-balance isolated pelvic perfusion

verfasst von: Keiko Nakazato, Chol Kim, Katsuyuki Terajima, Satoru Murata, Hitoshi Fujitani, Kazuhiro Nakanishi, Hiroyuki Tajima, Tatsuo Kumazaki, Atsuhiro Sakamoto

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Negative-balance isolated pelvic perfusion (NIPP) is used to administer high doses of anticancer drugs such as cisplatin to patients with advanced cancer of the pelvic region. Although the drugs are intended to be specifically delivered to the pelvis, their leakage into the systemic circulation can cause acute renal failure. This study examines the loading volume required for preservation of renal function during anesthesia of NIPP.

Methods

Pelvic cancer patients were assigned to NIPP according to its enrollment criteria. Patients with heart failure, uncontrollable hypertension, renal failure, pulmonary disease or contraindication for the contrast media were excluded. We compared the current anesthesia management regime with a previous protocol, with regard to the loading volume and renal function as assessed by the calculated glomerular filtration rate (GFR). The correlation between the total loading volume and the GFR ratio (GFR after NIPP/GFR before NIPP) was evaluated to define adequate volume loading.

Results

The GFR ratios were 0.86 ± 0.29 and 1.12 ± 0.25 for the previous and current procedures, respectively. The regression line showed that a minimum loading volume of 28.8 ml kg−1 h−1 was required to maintain a GFR ratio of ≥1.

Conclusions

A large volume infusion preserves the GFR despite high-dose cisplatin administration by NIPP.
Literatur
Zurück zum Zitat Al-Sarraf M, Fletcher W, Oishi N, Pugh R, Hewlett JS, Balducci L, McCracken J, Padilla F (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 66:31–35PubMed Al-Sarraf M, Fletcher W, Oishi N, Pugh R, Hewlett JS, Balducci L, McCracken J, Padilla F (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 66:31–35PubMed
Zurück zum Zitat Berkenstadt H, Ben-Ari G, Perel A (1998) Hemodynamic changes during a new procedure for regional chemotherapy involving occlusion of the thoracic aorta and inferior vena cava. J Clin Anesth 10:636–640PubMedCrossRef Berkenstadt H, Ben-Ari G, Perel A (1998) Hemodynamic changes during a new procedure for regional chemotherapy involving occlusion of the thoracic aorta and inferior vena cava. J Clin Anesth 10:636–640PubMedCrossRef
Zurück zum Zitat Creech O Jr, Krementz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148:616–632PubMedCrossRef Creech O Jr, Krementz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148:616–632PubMedCrossRef
Zurück zum Zitat Daugaard G (1990) Cisplatin nephrotoxicity: experimental and clinical studies. Dan Med Bull 37:1–12PubMed Daugaard G (1990) Cisplatin nephrotoxicity: experimental and clinical studies. Dan Med Bull 37:1–12PubMed
Zurück zum Zitat Daugaard G, Rossing N, Rorth M (1988) Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 21:163–167PubMedCrossRef Daugaard G, Rossing N, Rorth M (1988) Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 21:163–167PubMedCrossRef
Zurück zum Zitat Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470PubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470PubMed
Zurück zum Zitat MacLeod PM, Tyrell CJ, Keeling DH (1988) The effect of cisplatin on renal function in patients with testicular tumours. Clin Radiol 39:190–192PubMedCrossRef MacLeod PM, Tyrell CJ, Keeling DH (1988) The effect of cisplatin on renal function in patients with testicular tumours. Clin Radiol 39:190–192PubMedCrossRef
Zurück zum Zitat Murata S, Tajima H, Kusakai GI, Kumazaki T, Abe Y, Onozawa S, Komada Y, Kondo Y, Kimata R, Himeno S, Satake M (2005) Reduction of drug leakage by negative-balance isolated pelvic perfusion: correlation between leakage and in-out flow rate in a pig model. J Cancer Res Clin Oncol 131:575–580PubMedCrossRef Murata S, Tajima H, Kusakai GI, Kumazaki T, Abe Y, Onozawa S, Komada Y, Kondo Y, Kimata R, Himeno S, Satake M (2005) Reduction of drug leakage by negative-balance isolated pelvic perfusion: correlation between leakage and in-out flow rate in a pig model. J Cancer Res Clin Oncol 131:575–580PubMedCrossRef
Zurück zum Zitat Ostrow S, Egorin MJ, Hahn D, Markus S, Aisner J, Chang P, LeRoy A, Bachur NR, Wiernik PH (1981) High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep 65:73–78PubMed Ostrow S, Egorin MJ, Hahn D, Markus S, Aisner J, Chang P, LeRoy A, Bachur NR, Wiernik PH (1981) High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep 65:73–78PubMed
Zurück zum Zitat Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmes P (1994) Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 35:1–9PubMed Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmes P (1994) Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 35:1–9PubMed
Zurück zum Zitat Santoso JT, Lucci JA III, Coleman RL, Schafer I, Hannigan EV (2003) Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 52:13–18PubMedCrossRef Santoso JT, Lucci JA III, Coleman RL, Schafer I, Hannigan EV (2003) Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 52:13–18PubMedCrossRef
Zurück zum Zitat Strocchi E, Iaffaioli RV, Facchini G, Mantovani G, Ricci S, Cavallo G, Tortoriello A, D’Angelo R, Formato R, Rosato G, Fiore F, Iaccarino V, Petrella G, Memoli B, Santangelo M, Camaggi CM (2004) Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers. Eur J Surg Oncol 30:663–670PubMedCrossRef Strocchi E, Iaffaioli RV, Facchini G, Mantovani G, Ricci S, Cavallo G, Tortoriello A, D’Angelo R, Formato R, Rosato G, Fiore F, Iaccarino V, Petrella G, Memoli B, Santangelo M, Camaggi CM (2004) Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers. Eur J Surg Oncol 30:663–670PubMedCrossRef
Metadaten
Titel
Large volume loading to prevent cisplatin-induced nephrotoxicity during negative-balance isolated pelvic perfusion
verfasst von
Keiko Nakazato
Chol Kim
Katsuyuki Terajima
Satoru Murata
Hitoshi Fujitani
Kazuhiro Nakanishi
Hiroyuki Tajima
Tatsuo Kumazaki
Atsuhiro Sakamoto
Publikationsdatum
01.10.2007
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2007
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-007-0217-x

Weitere Artikel der Ausgabe 10/2007

Journal of Cancer Research and Clinical Oncology 10/2007 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.